Live feed
·
PRReleasevia Quantisnow
Skye Bioscience Inc. logo

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

ByQuantisnow·Wall Street's wire, on your screen.
SKYE· Skye Bioscience Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SKYE (Skye Bioscience Inc.) and more on Quantisnow.